Salud financiera de hoja de balance de BioRestorative Therapies

Salud financiera controles de criterios 6/6

BioRestorative Therapies tiene un patrimonio de los accionistas total de $10.0M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $14.6M y $4.6M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$13.09m
Patrimonio	US$9.99m
Total pasivo	US$4.58m
Activos totales	US$14.57m

Actualizaciones recientes sobre salud financiera

Recent updates

BioRestorative begins enrollment in mid-stage study of stem cell therapy for lumbar disk disease

Jun 30

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($13.5M) de BRTX superan a sus pasivos a corto plazo ($4.6M).

Pasivo a largo plazo: BRTX no tiene pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: BRTX está libre de deudas.

Reducción de la deuda: BRTX actualmente no tiene deuda, sin embargo, no podemos comparar con hace 5 años ya que no disponemos de datos de ese periodo.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: BRTX tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: BRTX dispone de suficiente cash runway para 1.4 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 6.2% cada año.

Salud financiera de hoja de balance de BioRestorative Therapies

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice Due to Failure to Timely File its Quarterly Report on Form 10-Q for the Fiscal Quarter Ended March 31, 2024

BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice Due to Failure to Timely File its Quarterly Report on Form 10-Q for the Fiscal Quarter Ended March 31, 2024

BioRestorative Therapies, Inc. announced delayed 10-Q filing

BioRestorative Therapies, Inc. announced delayed annual 10-K filing

First Amended Joint Reorganization Plan and Disclosure Statement Filed by BioRestorative Therapies, Inc.

Interim DIP Financing Approved for BioRestorative Therapies, Inc.

Recent updates

Consensus revenue estimates decrease by 17%, EPS upgraded

New major risk - Revenue and earnings growth

BioRestorative Therapies, Inc. Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data

BioRestorative Therapies, Inc. has filed a Follow-on Equity Offering in the amount of $3.61417 million.

BioRestorative Therapies, Inc. Receives Expanded Tissue License from New York State Department of Health

Consensus revenue estimates increase by 72%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

BioRestorative Therapies, Inc., Annual General Meeting, Sep 19, 2024

BioRestorative Therapies, Inc. to Report Q2, 2024 Results on Aug 13, 2024

BioRestorative Therapies, Inc. Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program

BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice Due to Failure to Timely File its Quarterly Report on Form 10-Q for the Fiscal Quarter Ended March 31, 2024

BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice Due to Failure to Timely File its Quarterly Report on Form 10-Q for the Fiscal Quarter Ended March 31, 2024

BioRestorative Therapies, Inc. announced delayed 10-Q filing

BioRestorative Therapies, Inc. Enhances Preclinical Metabolic Program with A Novel Exosome-Based Biologic Targeting Obesity

BioRestorative Therapies, Inc. to Report Q1, 2024 Results on May 14, 2024

Consensus revenue estimates increase by 20%, EPS downgraded

BioRestorative Therapies, Inc. Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment

BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease

Consensus EPS estimates upgraded to US$1.96 loss

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Shareholder dilution

Consensus revenue estimates increase by 12%

BioRestorative Therapies Presents Promising Data At Orthopaedic Research Society 2024 Annual Meeting

BioRestorative Therapies, Inc. Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease

New minor risk - Share price stability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 105%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

BioRestorative Therapies, Inc., Annual General Meeting, Sep 13, 2023

Biorestorative Therapies Inc. Receives License from New York State

BioRestorative Therapies, Inc. announced that it expects to receive $2.07565 million in funding

BioRestorative Therapies, Inc. Receives Unanimous Recommendation to Proceed in Its Phase 2 Clinical Trial for Chronic Lumbar Disc Disease, BRTX-100

BioRestorative Therapies, Inc. Receives Notice of Allowance by the Japanese Patent and Trademark Office for Patent Application Related to Its Thermostem Program

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

BioRestorative Therapies and Northwell Health Enter into Agreement to Participate in the Phase 2 Clinical Trial

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Biorestorative Therapies Announces Notice of Allowance by the European Patent Office for Patent Related to Its Thermostem(R) Program

BioRestorative Therapies Inc. Announces SBIR Phase I Grant to Explore the Therapeutic Effects of ThermoStem Targeting Polycystic Ovary Syndrome as an Indication

Third quarter 2022 earnings released: US$1.28 loss per share (vs US$4.99 loss in 3Q 2021)

High number of new and inexperienced directors

BioRestorative Therapies, Inc., Annual General Meeting, Nov 03, 2022

BioRestorative Therapies, Inc. Announces First Patient Enrolled for the Company's Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease

BioRestorative begins enrollment in mid-stage study of stem cell therapy for lumbar disk disease

Biorestorative Therapies, Inc. Announces Clinical Trial Contract with Second Site for the Company’S Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (Cldd)

BioRestorative Therapies Announces Clinical Site Initiation for the Company's Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease

BioRestorative Therapies, Inc. Announces Selection of 10 Clinical Sites for its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease

Biorestorative Therapies Announces It Has Initiated Its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease – Site Selection Underway

BioRestorative Therapies Announces Notice of Allowance for New Patent Application in Japan and Expansion of ThermoStem® IP Portfolio

BioRestorative Therapies, Inc. Announces Filing of Ten Patent Applications Related to its BRTX-100 Program

BioRestorative Therapies, Inc. Receives Notice of Allowance for Patent Application in Israel for Its Metabolic Program

BioRestorative Therapies Receives Patent in Japan Related to its Off-the-Shelf ThermoStem® Program

BioRestorative Therapies, Inc. announced delayed annual 10-K filing

Biorestorative Therapies, Inc. Elects Nickolay Kukekov as Director

BioRestorative Therapies, Inc. Announces Board Changes

BioRestorative Therapies, Inc. announced that it has received $0.6 million in funding

First Amended Joint Reorganization Plan and Disclosure Statement Filed by BioRestorative Therapies, Inc.

Interim DIP Financing Approved for BioRestorative Therapies, Inc.

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera